About GlomeriaTherapeutics
GlomeriaTherapeutics is a company based in Chieti (Italy) founded in 2010. GlomeriaTherapeutics has raised $1.13 million across 3 funding rounds from investors including European Union, Spindial and EIC Fund. GlomeriaTherapeutics offers products and services including Awareness Programs. GlomeriaTherapeutics operates in a competitive market with competitors including AWAK, Peripal, Relavo, Simergent and liberDi, among others.
- Headquarter Chieti, Italy
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.13 M (USD)
in 3 rounds
-
Latest Funding Round
$3.29 M (USD), Grant
Sep 30, 2018
-
Investors
European Union
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GlomeriaTherapeutics
GlomeriaTherapeutics offers a comprehensive portfolio of products and services, including Awareness Programs.
Initiatives to raise awareness and drive action against human sex trafficking
Funding Insights of GlomeriaTherapeutics
GlomeriaTherapeutics has successfully raised a total of $1.13M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $3.29 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GlomeriaTherapeutics
GlomeriaTherapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Spindial and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Sterilisation equipment is manufactured in Parma, Italy, since 2000.
|
Locked | Locked | Locked |
Investor details for GlomeriaTherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GlomeriaTherapeutics
Investment portfolio details for GlomeriaTherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GlomeriaTherapeutics
Detailed financials for GlomeriaTherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glomeriatherapeutics Comparisons
Peer comparison for GlomeriaTherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GlomeriaTherapeutics
GlomeriaTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AWAK, Peripal, Relavo, Simergent and liberDi, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Develops innovative portable digital dialysis devices for healthcare.
|
|
| Locked | Locked | Locked |
Develops innovative home-based devices for peritoneal dialysis treatments.
|
|
| Locked | Locked | Locked |
Development of dialysis devices for kidney failure patients is conducted.
|
|
| Locked | Locked | Locked |
Automated peritoneal dialysis systems are manufactured for home use.
|
|
| Locked | Locked | Locked |
Portable peritoneal dialysis systems are developed for end-stage kidney patients.
|
Detailed competitors of GlomeriaTherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glomeriatherapeutics
Complete news archive for GlomeriaTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GlomeriaTherapeutics
GlomeriaTherapeutics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
GlomeriaTherapeutics is headquartered in Chieti, Italy. It is registered at Chieti, Abruzzo, Italy.
GlomeriaTherapeutics is a funded company, having raised a total of $1.13M across 3 funding rounds to date.
Glomeria Therapeutics was founded in 2010 in Chieti, Italy, within the medical devices sector. Focus is placed on hospital products and therapy devices for patients with severe nephropathy and cardiopathy. Key offerings include SmartPD, an automated system for managing peritoneal dialysis solutions; DesmoPD, a secure connection system for peritoneal dialysis; and buffered solutions such as Glucothera with lactate or Alkathera with bicarbonate. Operations center on peritoneal dialysis advancements.
GlomeriaTherapeutics's top competitors include Simergent, liberDi and Padmaseetha Technologies.
GlomeriaTherapeutics offers Awareness Programs.
GlomeriaTherapeutics has 3 investors. Key investors include European Union, Spindial, and EIC Fund.